C.K. Cooper Reiterates Ligand Pharmaceuticals Buy, Raises PT

C.K. Cooper reiterated its Ligand Pharmaceuticals LGND Buy rating increased its Ligand price target from $21 to $24 in a research report published today. In the report, C.K. Cooper states, "We reiterate our BUY rating and are increasing our price target from $21.00 to $24.00 as a result of the total Net Present Value (NPV) of cash, milestones, and royalties for products that are currently marketed, as well as later-stage (Phase II and III) compounds in various levels of development through to 2020." Shares of Ligand Pharmaceuticals were trading at $13.32 at the time of posting, up 7.42% from Monday's market close.